Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.64 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574405 | 0.92 | KIF11 (0.75) | KIF11STAT3KDM4EMAPT | |
| SCHEMBL3579533 | 0.92 | KIF11 (0.61) | KIF11STAT3KDM4EMAPTLMNA | |
| SCHEMBL3576268 | 0.87 | KIF11 (0.82) | KIF11LMNA | |
| SCHEMBL3577177 | 0.84 | KIF11 (0.72) | KIF11MAPT | |
| SCHEMBL3579490 | 0.83 | KIF11 (0.65) | KIF11MAPTLMNA | |
| SCHEMBL3630990 | 0.83 | KIF11 (0.75) | KIF11KDM4EMAPT | |
| SCHEMBL3568514 | 0.78 | KIF11 (1.00) | KIF11 | |
| SCHEMBL3574099 | 0.77 | KIF11 (0.83) | KIF11MAPTLMNA | |
| SCHEMBL3579797 | 0.77 | KIF11 (1.00) | KIF11STAT3 | |
| SCHEMBL3571009 | 0.76 | KIF11 (0.83) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855295-B2 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855295-B2 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855295-B2 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20050215580-A1 | Tetrahydrocarboline compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215580-A1 | Tetrahydrocarboline compounds as anticancer agents | MTHFD1, BAD, DHFR | KIF11 2735/4885STAT3 2377/4885KDM4E 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.